Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EBITDA: 2009-2025

Historic EBITDA for Rockwell Medical (RMTI) over the last 17 years, with Sep 2025 value amounting to -$1.6 million.

  • Rockwell Medical's EBITDA fell 181.82% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.8 million, marking a year-over-year decrease of 929.66%. This contributed to the annual value of $608,000 for FY2024, which is 109.12% up from last year.
  • Rockwell Medical's EBITDA amounted to -$1.6 million in Q3 2025, which was down 17.42% from -$1.3 million recorded in Q2 2025.
  • Rockwell Medical's 5-year EBITDA high stood at $1.9 million for Q3 2024, and its period low was -$8.4 million during Q4 2021.
  • Moreover, its 3-year median value for EBITDA was -$1.3 million (2025), whereas its average is -$941,364.
  • In the last 5 years, Rockwell Medical's EBITDA soared by 211.46% in 2024 and then tumbled by 361.94% in 2025.
  • Rockwell Medical's EBITDA (Quarterly) stood at -$8.4 million in 2021, then spiked by 76.48% to -$2.0 million in 2022, then spiked by 72.18% to -$547,000 in 2023, then climbed by 5.12% to -$519,000 in 2024, then plummeted by 181.82% to -$1.6 million in 2025.
  • Its EBITDA stands at -$1.6 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$1.4 million for Q1 2025.